查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1722140

第一代肝细胞市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2025年～2032年按)- 各产品，类别，用途/化验，各终端用户，各地区，各企业)

Primary Hepatocytes Market - Global Primary Hepatocytes Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product, By Species, By Application/Assay, By End User, By Geographic Coverage and By Company)
出版日期: | 出版商: Fairfield Market Research | 英文 180 Pages | 商品交期: 2-5个工作天内

价格
简介目录

预计未来几年全球原代肝细胞市场规模将大幅成长，到2032年将达到4.069亿美元。这比2025年的2.636亿美元大幅成长，反映出2025年至2032年预测期间的复合年增长率（CAGR）为6.4%。这种快速增长主要得益于肝臟相关疾病盛行率的上升，以及药物开发和毒性测试中对更具预测性的体外模型日益增长的需求。

市场洞察

原代肝细胞已成为肝病研究、临床前药物检查和毒理学评估的基石。它们能够精确模拟肝功能，使其成为研究药物代谢、酵素活性和肝毒性的理想选择。 3D培养系统的最新进展，例如球状体和共培养技术，使得更忠实地模拟体内肝臟微环境成为可能，从而增强了基于肝细胞的检测方法的实用性。

越来越多的研究人员和製药公司开始使用干细胞衍生的肝细胞，以克服供应限制，同时保持其功能完整性。这种趋势，加上人们对伦理研究实践日益增长的兴趣以及减少动物试验的监管压力，正在推动基于肝细胞的体外系统广泛应用。

市场推动因素

市场推动因素之一是肝病发生率的上升，包括非酒精性脂肪性肝病 (NAFLD) 和肝炎。这些疾病催生了对可靠体外模型的需求，这些模型能够有效地支持药物研发和治疗测试。原代肝细胞与人类肝细胞较接近，是这方面的重要工具。

推动市场成长的另一个主要因素是全球癌症发生率的上升。世界卫生组织 (WHO) 预测，到 2040 年，癌症患者将增加 47%，这凸显了对更有效的药物筛选方法的迫切需求。 3D 肝细胞模型在评估药物毒性和疗效方面具有更高的预测能力，使其在肿瘤学研究中具有不可估量的价值。龙沙 (Lonza) 和赛默飞世尔科技 (Thermo Fisher Scientific) 等领先公司正在积极投资器官晶片和 3D 肝细胞模型，以满足这一需求。

此外，FDA 和 EMA 等监管机构正在强调使用与人类相关的体外模型来改善早期药物筛选并减少动物试验。此类监管支持进一步巩固了原代肝细胞在现代药物研发中的作用。

商机

这个市场充满了商机，尤其是人们对3D细胞培养技术的兴趣日益浓厚。这些系统能够重现复杂的组织结构，并能更准确地洞察肿瘤生长、转移和抗药性等生物过程。由患者来源的细胞建构的类器官正在为个人化医疗应用铺平道路。

此外，更严格的动物实验法规为基于肝细胞的模型开闢了新的途径。企业正在利用这一转变，开发符合不断发展的伦理标准的创新筛选工具，同时提高临床前研究的可靠性。对可扩展且经济高效的解决方案的需求，为新创公司和新兴企业创造了创新和拓展业务的机会。

区域分析

北美仍是全球原代肝细胞市场的主导地区。先进的医疗基础设施、大量的研发投入以及强大的製药和生物技术公司占据关键地位。高发病率的肝病和支持创新药物开发的监管环境也推动了需求的成长。

欧洲也是成长强劲的领先地区之一，这得益于成熟的製药业和先进的监管政策。德国、法国和英国等国正率先将体外系统纳入其药物开发流程。欧洲药品管理局 (EMA) 持续推广动物试验的替代方案，鼓励更广泛地采用原代肝细胞。

主要参与者

竞争格局的特征是策略投资、产品创新以及产业领袖之间的联盟。各公司正致力于改善细胞分离、冷冻保存和检测适用性，以满足不断变化的市场需求。

近期产业趋势

2024年3月，默克公司在上海投资1,400万美元，成立了M Lab™合作中心，以扩展其新的生物应用和培训实验室，从而支持生物製药研究。

2024年2月，默克公司在巴西圣保罗投资2,000万美元开设了一个物流中心，以提高服务拉丁美洲生命科学客户的效率。

2023年2月，ATCC与美国药典(USP)建立长期合作伙伴关係，共同开发生物製剂参考物质和标准，以提高品质和合规性。

市场区隔

各产品

  • 冻存悬浮肝细胞
  • 新鲜悬浮肝细胞
  • 3D（球状）肝细胞
  • 扩增肝细胞（可接种）
  • 去特化肝细胞

类别

  • 人
  • 大鼠
  • 小鼠
  • 狗
  • 猴子
  • 马
  • 其他

各用途/化验

  • 细胞活力测定
  • 细胞色素酶活性测定
  • 高含量细胞毒性测定
  • 转运蛋白抑制测定
  • 在体外内源性清除
  • 磷脂测定
  • 其他

各终端用户

  • 生物製药公司
  • 学术研究机关
  • 受託研究机构

各地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东·非洲

本报告提供全球第一代肝细胞市场相关调查，市场概要，以及各产品，类别，用途/化验，各终端用户，向各地区趋势，及市场参与市场企业的竞争趋势等资讯。

目录

第1章 摘要整理

第2章 市场概要

  • 市场定义和市场区隔
  • 市场动态
  • 价值链分析
  • 波特的五力分析
  • COVID-19影响分析
  • 经济概要
  • 大环境分析
  • 第一代肝细胞市场，产品的招聘
  • 各地区的法规情势
  • 价值链分析

第3章 全球第一代肝细胞市场预测，2019年～2032年

  • 全球第一代肝细胞市场预测:各产品，金额(100万美元)，2019年～2032年
  • 全球第一代肝细胞市场预测:类别，金额(100万美元)，2019年～2032年
  • 全球第一代肝细胞市场预测:各用途/化验，金额(100万美元)，2019-2032年
  • 全球第一代肝细胞市场预测:各终端用户，金额(100万美元)，2019年～2032年
  • 全球第一代肝细胞市场预测:各地区，金额(100万美元)，2019年～2032年

第4章 北美的第一代肝细胞市场预测，2019年～2032年

第5章 欧洲的第一代肝细胞市场预测，2019年～2032年

第6章 亚太地区的第一代肝细胞市场预测，2019年～2032年

第7章 南美的第一代肝细胞市场预测，2019年～2032年

第8章 中东·非洲的第一代肝细胞市场预测，2019年～2032年

第9章 竞争情形

  • 2025年的企业市场占有率分析
  • 竞争仪表板
  • 企业简介
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Lonza
    • Takara Bio Inc.
    • American Type Culture Collection (ATCC)
    • Corning Inc.
    • Cell Biologics, Inc.
    • Creative Bioarray
    • Axol Bioscience Ltd.
    • HiMedia Laboratories
    • NEXEL Co., Ltd.
    • AnaBios
    • Cytes Biotechnologies S.L.
    • ZenBio, Inc. (BioIVT)
    • iXCells Biotechnologies
    • ScienCell Research Laboratories, Inc.
    • Kerafast
    • Kosheeka
    • XenoTech
    • LifeNet Health LifeSciences
    • Cell Guidance Systems LLC
    • Applied Biological Materials Inc. (abm)
    • Discovery Life Sciences
    • Innoprot
    • Novabiosis

第10章 附录

简介目录

The global primary hepatocytes market is poised for substantial growth over the coming years, reaching an estimated valuation of US$ 406.9 million by 2032. This marks a significant increase from the US$ 263.6 million recorded in 2025, reflecting a compound annual growth rate (CAGR) of 6.4% during the forecast period from 2025 to 2032. The surge is largely attributed to the escalating prevalence of liver-related diseases and the increasing demand for more predictive in vitro models in drug development and toxicology testing.

Market Insights

Primary hepatocytes have become a cornerstone in liver disease research, preclinical drug testing, and toxicological assessments. Their ability to accurately mimic liver function makes them ideal for investigating drug metabolism, enzyme activity, and hepatotoxicity. Recent advancements in 3D culture systems, such as spheroids and co-culture technologies, are elevating the relevance of hepatocyte-based assays by enabling closer simulation of the in vivo liver microenvironment.

Researchers and pharmaceutical companies are increasingly turning to stem cell-derived hepatocytes to overcome supply limitations while maintaining functional integrity. This trend, coupled with a growing focus on ethical research practices and regulatory pressure to reduce animal testing, is driving the widespread adoption of hepatocyte-based in vitro systems.

Market Drivers

One of the key drivers of the market is the increasing incidence of liver diseases, including Non-Alcoholic Fatty Liver Disease (NAFLD) and hepatitis. These conditions are generating demand for reliable in vitro models that can effectively support drug discovery and therapeutic testing. Primary hepatocytes, which offer a close representation of human liver cells, are essential tools in this regard.

Another major factor fueling market growth is the global rise in cancer prevalence. The World Health Organization (WHO) anticipates a 47% increase in cancer cases by 2040, which underscores the urgent need for more effective drug screening methods. 3D hepatocyte models are proving invaluable in oncology research, offering greater predictive power in assessing drug toxicity and efficacy. Leading companies such as Lonza and Thermo Fisher Scientific are actively investing in organ-on-a-chip and 3D liver models to meet this demand.

Additionally, regulatory bodies like the FDA and EMA are emphasizing the use of human-relevant in vitro models to improve early-stage drug screening and reduce animal testing. This regulatory support is further solidifying the role of primary hepatocytes in modern drug development.

Business Opportunities

The market is brimming with opportunities, especially in the wake of growing interest in 3D cell culture technologies. These systems replicate complex tissue architecture, offering more accurate insights into biological processes such as tumor growth, metastasis, and drug resistance. Organoids created from patient-derived cells are paving the way for personalized medicine applications.

Moreover, stricter animal testing regulations are opening new avenues for hepatocyte-based models. Companies are capitalizing on this shift by developing innovative screening tools that align with evolving ethical standards while enhancing the reliability of preclinical studies. The demand for scalable, cost-effective solutions also presents opportunities for startups and emerging players to innovate and expand.

Regional Analysis

North America remains the dominant region in the global primary hepatocytes market. Its advanced healthcare infrastructure, substantial investment in R&D, and strong presence of pharmaceutical and biotechnology companies contribute to its leading position. The high incidence of liver disorders and a regulatory environment that supports innovative drug development practices are also driving demand.

Europe is another key region experiencing robust growth, fueled by its well-established pharmaceutical sector and progressive regulatory policies. Countries like Germany, France, and the United Kingdom are leading efforts in integrating in vitro systems into drug development pipelines. The European Medicines Agency (EMA) continues to promote alternatives to animal testing, thereby supporting increased adoption of primary hepatocytes.

Key Players

The competitive landscape is characterized by strategic investments, product innovations, and collaborations among major industry players. Companies are focusing on improving cell isolation techniques, cryopreservation technologies, and assay compatibility to meet the evolving demands of the market.

Prominent players in the primary hepatocytes market include:

  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza
  • Takara Bio Inc.
  • American Type Culture Collection (ATCC)
  • Corning Inc.
  • Cell Biologics, Inc.
  • Creative Bioarray
  • Axol Bioscience Ltd.
  • HiMedia Laboratories
  • AnaBios
  • Cytes Biotechnologies S.L.
  • ZenBio, Inc. (BioIVT)
  • iXCells Biotechnologies
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Kosheeka
  • XenoTech
  • LifeNet Health LifeSciences
  • Applied Biological Materials Inc. (abm)
  • Discovery Life Sciences
  • Innoprot
  • Novabiosis

Recent Industry Developments

In March 2024, Merck invested US$ 14 million in its M Lab(TM) Collaboration Center in Shanghai, expanding its offerings with new biological application and training labs to support biopharma research.

In February 2024, Merck opened a US$ 20 million distribution center in Sao Paulo, Brazil, aimed at improving service efficiency for its life science clients in Latin America.

In February 2023, ATCC entered a long-term partnership with the U.S. Pharmacopeia (USP) to co-develop reference materials and standards for biologic medicines, bolstering quality and compliance.

Market Segmentation

By Product:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

By Species:

  • Human
  • Rat
  • Mouse
  • Dog
  • Monkey
  • Horse
  • Others

By Application/Assay:

  • Cell Viability Assay
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assay
  • In Vitro Intrinsic Clearance
  • Phospholipids Assay
  • Others

By End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Economic Overview
    • 2.6.1. World Economic Projections
  • 2.7. PESTLE Analysis
  • 2.8. Primary Hepatocytes Market, Product Adoption
  • 2.9. Regulatory Scenario by Region
  • 2.10. Value Chain Analysis

3. Global Primary Hepatocytes Market Outlook, 2019-2032

  • 3.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cryopreserved Suspension Hepatocytes
      • 3.1.1.2. Fresh Suspension Hepatocytes
      • 3.1.1.3. 3D (Spheroid) Hepatocytes
      • 3.1.1.4. Expanded Hepatocytes (Plateable)
      • 3.1.1.5. Non-characterized Hepatocytes
  • 3.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Human
      • 3.2.1.2. Rat
      • 3.2.1.3. Mouse
      • 3.2.1.4. Dog
      • 3.2.1.5. Monkey
      • 3.2.1.6. Horse
      • 3.2.1.7. Others
  • 3.3. Global Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. Cell Viability Assay
      • 3.3.1.2. Cytochrome Enzyme Activity
      • 3.3.1.3. High Content Cytotoxicity
      • 3.3.1.4. Transporter Inhibition Assay
      • 3.3.1.5. In Vitro Intrinsic Clearance
      • 3.3.1.6. Phospholipids Assay
      • 3.3.1.7. Others
  • 3.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 3.4.1. Key Highlights
      • 3.4.1.1. Biopharmaceutical companies
      • 3.4.1.2. Academic and Research institutes
      • 3.4.1.3. Contract Research Organizations
  • 3.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn), 2019-2032
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. East Asia
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Primary Hepatocytes Market Outlook, 2019-2032

  • 4.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Cryopreserved Suspension Hepatocytes
      • 4.1.1.2. Fresh Suspension Hepatocytes
      • 4.1.1.3. 3D (Spheroid) Hepatocytes
      • 4.1.1.4. Expanded Hepatocytes (Plateable)
      • 4.1.1.5. Non-characterized Hepatocytes
  • 4.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Human
      • 4.2.1.2. Rat
      • 4.2.1.3. Mouse
      • 4.2.1.4. Dog
      • 4.2.1.5. Monkey
      • 4.2.1.6. Horse
      • 4.2.1.7. Others
  • 4.3. North America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Cell Viability Assay
      • 4.3.1.2. Cytochrome Enzyme Activity
      • 4.3.1.3. High Content Cytotoxicity
      • 4.3.1.4. Transporter Inhibition Assay
      • 4.3.1.5. In Vitro Intrinsic Clearance
      • 4.3.1.6. Phospholipids Assay
      • 4.3.1.7. Others
  • 4.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. Biopharmaceutical companies
      • 4.4.1.2. Academic and Research institutes
      • 4.4.1.3. Contract Research Organizations
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.3. U.S. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 4.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.7. Canada Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Primary Hepatocytes Market Outlook, 2019-2032

  • 5.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cryopreserved Suspension Hepatocytes
      • 5.1.1.2. Fresh Suspension Hepatocytes
      • 5.1.1.3. 3D (Spheroid) Hepatocytes
      • 5.1.1.4. Expanded Hepatocytes (Plateable)
      • 5.1.1.5. Non-characterized Hepatocytes
  • 5.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Human
      • 5.2.1.2. Rat
      • 5.2.1.3. Mouse
      • 5.2.1.4. Dog
      • 5.2.1.5. Monkey
      • 5.2.1.6. Horse
      • 5.2.1.7. Others
  • 5.3. Europe Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cell Viability Assay
      • 5.3.1.2. Cytochrome Enzyme Activity
      • 5.3.1.3. High Content Cytotoxicity
      • 5.3.1.4. Transporter Inhibition Assay
      • 5.3.1.5. In Vitro Intrinsic Clearance
      • 5.3.1.6. Phospholipids Assay
      • 5.3.1.7. Others
  • 5.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Biopharmaceutical companies
      • 5.4.1.2. Academic and Research institutes
      • 5.4.1.3. Contract Research Organizations
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.3. Germany Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.7. U.K. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.11. France Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.13. Spain Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.14. Spain Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.15. Spain Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.16. Spain Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.17. Italy Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.18. Italy Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.19. Italy Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.20. Italy Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.23. Russia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.27. Rest of Europe Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia & Pacific Primary Hepatocytes Market Outlook, 2019-2032

  • 6.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cryopreserved Suspension Hepatocytes
      • 6.1.1.2. Fresh Suspension Hepatocytes
      • 6.1.1.3. 3D (Spheroid) Hepatocytes
      • 6.1.1.4. Expanded Hepatocytes (Plateable)
      • 6.1.1.5. Non-characterized Hepatocytes
  • 6.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Human
      • 6.2.1.2. Rat
      • 6.2.1.3. Mouse
      • 6.2.1.4. Dog
      • 6.2.1.5. Monkey
      • 6.2.1.6. Horse
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cell Viability Assay
      • 6.3.1.2. Cytochrome Enzyme Activity
      • 6.3.1.3. High Content Cytotoxicity
      • 6.3.1.4. Transporter Inhibition Assay
      • 6.3.1.5. In Vitro Intrinsic Clearance
      • 6.3.1.6. Phospholipids Assay
      • 6.3.1.7. Others
  • 6.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Biopharmaceutical companies
      • 6.4.1.2. Academic and Research institutes
      • 6.4.1.3. Contract Research Organizations
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia & Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.3. China Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.7. Japan Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.11. South Korea Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.15. India Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.19. Southeast Asia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Primary Hepatocytes Market Outlook, 2019-2032

  • 7.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cryopreserved Suspension Hepatocytes
      • 7.1.1.2. Fresh Suspension Hepatocytes
      • 7.1.1.3. 3D (Spheroid) Hepatocytes
      • 7.1.1.4. Expanded Hepatocytes (Plateable)
      • 7.1.1.5. Non-characterized Hepatocytes
  • 7.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Human
      • 7.2.1.2. Rat
      • 7.2.1.3. Mouse
      • 7.2.1.4. Dog
      • 7.2.1.5. Monkey
      • 7.2.1.6. Horse
      • 7.2.1.7. Others
  • 7.3. Latin America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cell Viability Assay
      • 7.3.1.2. Cytochrome Enzyme Activity
      • 7.3.1.3. High Content Cytotoxicity
      • 7.3.1.4. Transporter Inhibition Assay
      • 7.3.1.5. In Vitro Intrinsic Clearance
      • 7.3.1.6. Phospholipids Assay
      • 7.3.1.7. Others
  • 7.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Biopharmaceutical companies
      • 7.4.1.2. Academic and Research institutes
      • 7.4.1.3. Contract Research Organizations
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.3. Brazil Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.7. Mexico Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.9. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.10. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.11. Rest of Latin America Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.12. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Primary Hepatocytes Market Outlook, 2019-2032

  • 8.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cryopreserved Suspension Hepatocytes
      • 8.1.1.2. Fresh Suspension Hepatocytes
      • 8.1.1.3. 3D (Spheroid) Hepatocytes
      • 8.1.1.4. Expanded Hepatocytes (Plateable)
      • 8.1.1.5. Non-characterized Hepatocytes
  • 8.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Human
      • 8.2.1.2. Rat
      • 8.2.1.3. Mouse
      • 8.2.1.4. Dog
      • 8.2.1.5. Monkey
      • 8.2.1.6. Horse
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cell Viability Assay
      • 8.3.1.2. Cytochrome Enzyme Activity
      • 8.3.1.3. High Content Cytotoxicity
      • 8.3.1.4. Transporter Inhibition Assay
      • 8.3.1.5. In Vitro Intrinsic Clearance
      • 8.3.1.6. Phospholipids Assay
      • 8.3.1.7. Others
  • 8.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Biopharmaceutical companies
      • 8.4.1.2. Academic and Research institutes
      • 8.4.1.3. Contract Research Organizations
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Countries Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.2. GCC Countries Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.3. GCC Countries Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.4. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.7. South Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.8. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.9. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.10. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.11. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.12. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.15. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Thermo Fisher Scientific Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Merck KGaA
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. Lonza
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. Takara Bio Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. American Type Culture Collection (ATCC)
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Corning Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. Cell Biologics, Inc.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Creative Bioarray
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Axol Bioscience Ltd.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. HiMedia Laboratories
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development
    • 9.3.11. NEXEL Co., Ltd.
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Product Portfolio
      • 9.3.11.3. Financial Overview
      • 9.3.11.4. Business Strategies and Development
    • 9.3.12. AnaBios
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Product Portfolio
      • 9.3.12.3. Financial Overview
      • 9.3.12.4. Business Strategies and Development
    • 9.3.13. Cytes Biotechnologies S.L.
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Product Portfolio
      • 9.3.13.3. Financial Overview
      • 9.3.13.4. Business Strategies and Development
    • 9.3.14. ZenBio, Inc. (BioIVT)
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Product Portfolio
      • 9.3.14.3. Financial Overview
      • 9.3.14.4. Business Strategies and Development
    • 9.3.15. iXCells Biotechnologies
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Product Portfolio
      • 9.3.15.3. Financial Overview
      • 9.3.15.4. Business Strategies and Development
    • 9.3.16. ScienCell Research Laboratories, Inc.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Product Portfolio
      • 9.3.16.3. Financial Overview
      • 9.3.16.4. Business Strategies and Development
    • 9.3.17. Kerafast
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Product Portfolio
      • 9.3.17.3. Financial Overview
      • 9.3.17.4. Business Strategies and Development
    • 9.3.18. Kosheeka
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Product Portfolio
      • 9.3.18.3. Financial Overview
      • 9.3.18.4. Business Strategies and Development
    • 9.3.19. XenoTech
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Product Portfolio
      • 9.3.19.3. Financial Overview
      • 9.3.19.4. Business Strategies and Development
    • 9.3.20. LifeNet Health LifeSciences
      • 9.3.20.1. Company Overview
      • 9.3.20.2. Product Portfolio
      • 9.3.20.3. Financial Overview
      • 9.3.20.4. Business Strategies and Development
    • 9.3.21. Cell Guidance Systems LLC
      • 9.3.21.1. Company Overview
      • 9.3.21.2. Product Portfolio
      • 9.3.21.3. Financial Overview
      • 9.3.21.4. Business Strategies and Development
    • 9.3.22. Applied Biological Materials Inc. (abm)
      • 9.3.22.1. Company Overview
      • 9.3.22.2. Product Portfolio
      • 9.3.22.3. Financial Overview
      • 9.3.22.4. Business Strategies and Development
    • 9.3.23. Discovery Life Sciences
      • 9.3.23.1. Company Overview
      • 9.3.23.2. Product Portfolio
      • 9.3.23.3. Financial Overview
      • 9.3.23.4. Business Strategies and Development
    • 9.3.24. Innoprot
      • 9.3.24.1. Company Overview
      • 9.3.24.2. Product Portfolio
      • 9.3.24.3. Financial Overview
      • 9.3.24.4. Business Strategies and Development
    • 9.3.25. Novabiosis
      • 9.3.25.1. Company Overview
      • 9.3.25.2. Product Portfolio
      • 9.3.25.3. Financial Overview
      • 9.3.25.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations